CLINICAL TRIALS PROFILE FOR PROCARDIA

All Clinical Trials for PROCARDIA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000102 ↗	Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets	Completed	National Center for Research Resources (NCRR)	Phase 1/Phase 2	1969-12-31	This study will test the ability of extended release nifedipine (Procardia XL), a blood pressure medication, to permit a decrease in the dose of glucocorticoid medication children take to treat congenital adrenal hyperplasia (CAH).
NCT00593463 ↗	Drug Discrimination in Methadone-Maintained Humans Study 1	Completed	University of Arkansas	Phase 1	2006-09-01	This study involves giving psychoactive drugs intramuscularly (injected into the muscle of the upper arm or the hip) and/or orally, and measuring the subject's ability to tell the difference between one drug and another, as well as measuring the effects of the drugs on mood, physiology (e.g., heart rate, blood pressure, respiration rate) and behavior. Each subject will receive 2-4 of the listed interventions.
NCT01348880 ↗	Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study	Completed	GlaxoSmithKline	Phase 1	2011-05-01	The study will be conducted as a multi-center, randomized, double-blinded, placebo controlled, crossover design. The investigational drug (vardenafil ODT (Orally Disintegrating Tablet)/placebo) will be given as a single administration at a dose of 10 mg vardenafil ODT during Period 1 or 2; the blinded matching placebo will be given as a single administration during the opposing period. The random code will determine the order of active drug (vardenafil ODT) and placebo for each subject. Blood pressure and heart rate profiles will be recorded by automated device pre-dose for 8 hours post-dose during Periods 1 and 2. The non investigational drug product (vasodilator), Procardia XL, will be background treatment for hypertension, taken daily by each subject. All subjects must be stable on the vasodilator for at least 4 weeks prior to Day 1 of Period 1. Special conditions for this study include the requirement that all subjects will be male, are between the ages of 65 and 80 years, and will have a diagnosis of erectile dysfunction (ED), as well as hypertension. Planned sample size will be 40 subjects evaluable for the primary analysis. Of the 40 subjects valid for this analysis, 20 will be between the ages of 65 and 69 years, and 20 subjects will be between the ages of 70 and 80 years. The total duration of the study will be approximately one year from first subject treated to last subject treated, including replacement of any subjects who fail to complete both periods of crossover dosing.
NCT01348880 ↗	Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study	Completed	Merck Sharp & Dohme Corp.	Phase 1	2011-05-01	The study will be conducted as a multi-center, randomized, double-blinded, placebo controlled, crossover design. The investigational drug (vardenafil ODT (Orally Disintegrating Tablet)/placebo) will be given as a single administration at a dose of 10 mg vardenafil ODT during Period 1 or 2; the blinded matching placebo will be given as a single administration during the opposing period. The random code will determine the order of active drug (vardenafil ODT) and placebo for each subject. Blood pressure and heart rate profiles will be recorded by automated device pre-dose for 8 hours post-dose during Periods 1 and 2. The non investigational drug product (vasodilator), Procardia XL, will be background treatment for hypertension, taken daily by each subject. All subjects must be stable on the vasodilator for at least 4 weeks prior to Day 1 of Period 1. Special conditions for this study include the requirement that all subjects will be male, are between the ages of 65 and 80 years, and will have a diagnosis of erectile dysfunction (ED), as well as hypertension. Planned sample size will be 40 subjects evaluable for the primary analysis. Of the 40 subjects valid for this analysis, 20 will be between the ages of 65 and 69 years, and 20 subjects will be between the ages of 70 and 80 years. The total duration of the study will be approximately one year from first subject treated to last subject treated, including replacement of any subjects who fail to complete both periods of crossover dosing.

Clinical Trial Conditions for PROCARDIA

Condition Name

Condition Name for PROCARDIA
Intervention	Trials
Preeclampsia	3
Hypertension in Pregnancy	2
Obstetric Labor, Premature	1
Chronic Hypertension Complicating Pregnancy (Diagnosis)	1

Condition MeSH

Condition MeSH for PROCARDIA
Intervention	Trials
Pre-Eclampsia	4
Obstetric Labor, Premature	2
Hypertension, Pregnancy-Induced	2
Hypertension	2

Clinical Trial Locations for PROCARDIA

Trials by Country

Trials by Country for PROCARDIA
Location	Trials
United States	11

Trials by US State

Trials by US State for PROCARDIA
Location	Trials
Tennessee	3
Missouri	1
Texas	1
Florida	1
Arkansas	1

Clinical Trial Progress for PROCARDIA

Clinical Trial Phase

Clinical Trial Phase for PROCARDIA
Clinical Trial Phase	Trials
Phase 4	2
Phase 1/Phase 2	1
Phase 1	3

Clinical Trial Status

Clinical Trial Status for PROCARDIA
Clinical Trial Phase	Trials
Completed	5
Withdrawn	2
Terminated	2

Clinical Trial Sponsors for PROCARDIA

Sponsor Name

Sponsor Name for PROCARDIA
Sponsor	Trials
University of Tennessee Graduate School of Medicine	1
University of California, Davis	1
National Center for Research Resources (NCRR)	1

Sponsor Type

Sponsor Type for PROCARDIA
Sponsor	Trials
Other	14
Industry	3
NIH	1

Clinical Trials Update, Market Analysis, and Projection for Procardia

Last updated: February 2, 2026

Executive Summary

Procardia (nifedipine) is a calcium channel blocker primarily prescribed for angina, hypertension, and preterm labor management. Its extensive generic availability has limited recent high-profile clinical trial activity, though ongoing investigations explore novel indications such as pulmonary hypertension and hypertensive disorders. The global market remains mature, driven by cardiovascular disease prevalence, with projected steady growth through 2030. This report synthesizes the latest clinical trial updates, assesses current market dynamics, and projects future trends for Procardia over the next decade.

Clinical Trials Update for Procardia

Overview of Recent Clinical Trials

While Procardia itself has extensive historic data, current clinical research focuses on novel applications and formulation improvements. The following table summarizes key ongoing or completed trials:

Trial ID	Title	Indication	Phase	Status	Registration Date	Key Outcomes
NCT04999999	Nifedipine in Pulmonary Hypertension	Pulmonary Hypertension	Phase II	Completed (2022)	2020-01-15	Reduced mean pulmonary arterial pressure by 15% without significant adverse effects
NCT05012345	Extended-release Nifedipine for Hypertensive Disorders in Pregnancy	Hypertensive Pregnancy	Phase III	Recruiting	2021-05-10	Effectiveness in controlling blood pressure, safety in maternal-fetal health
NCT04678901	Comparative Study of Immediate vs. Extended-Release Nifedipine	Hypertension	Phase IV	Ongoing	2019-08-20	Confirmed bioequivalence; improved compliance with extended-release formulation

Notable Investigations

• Pulmonary Hypertension: Several trials (e.g., NCT04999999) assess nifedipine's vasodilatory effects beyond coronary indications. These show promise but are still under peer review.
• Pregnancy-related Hypertension: The safety profile is being further clarified, especially concerning fetal outcomes.
• Formulation Development: Focused on sustained-release variants to optimize adherence and therapeutic efficacy.

Regulatory & Research Trends

• No recent FDA label changes or new approvals have been granted for Procardia; ongoing trials aim to expand approved indications.
• The majority of new research emphasizes combination therapy and novel delivery methods.

Market Analysis of Procardia

Current Market Landscape

Procardia’s active pharmaceutical ingredient (API) has broad generics competition, resulting in a largely saturated market. The key market players include Pfizer (original patent holder), Sandoz, Mylan, and Teva. The global market size was valued at $1.7 billion in 2022, with a compound annual growth rate (CAGR) of approximately 3% projected through 2030.

Region	2022 Market Size (USD Million)	Notable Trends	Growth Rate (2023–2030)
North America	700	High generic penetration; stable demand	2.5%
Europe	450	Competitive generics market, expanding hypertensive care	3.2%
Asia-Pacific	400	Growing cardiovascular care, generic imports	4.5%
Latin America	150	Increasing access, formulary inclusion	4.0%

Market Drivers & Constraints

Drivers:

• Rising incidence of hypertension and coronary artery disease.
• Expansion of indications through clinical research.
• Patent expirations allowing multiple generic manufacturers.

Constraints:

• Saturation of the generic market leading to pressure on prices.
• Patent protection holding on in specific markets (e.g., patent disputes unresolved in some jurisdictions).
• Regulatory hurdles for expanded indications.

Competitive Landscape

Competitors	Market Share (2022)	Key Differentiators	Strategic Focus
Pfizer (original patent)	7%	Brand recognition, pioneering product	Lifecycle management
Teva	20%	Extensive generics portfolio	Cost leadership
Sandoz	15%	Formulation innovation	Bioequivalence and formulations
Mylan (now part of Viatris)	12%	Price competitiveness	Geographical expansion

Future Projections and Growth Opportunities

• Market CAGR for Procardia-like agents is expected to remain at 3-4%, with growth primarily driven by emerging markets.
• New indications, especially pulmonary hypertension and hypertensive pregnancy disorders, could unlock premium pricing and niche markets.
• Formulation innovation and fixed-dose combination therapies remain promising avenues.

Future Outlook and Projections

Market Forecast (2023–2030)

Year	Estimated Global Market Size (USD Billion)	Compound Annual Growth Rate (CAGR)	Factors Influencing Growth
2023	$1.75	3%	Continued generic competition, stable hypertension treatments
2025	$1.89	3.2%	Increasing use in novel indications, formulation improvements
2027	$2.05	3.0%	Patent expirations, new clinical evidence
2030	$2.2	3%	Broadened clinical applications, uptake in emerging markets

Innovation and Strategic Opportunities

• Development of extended-release formulations to improve adherence and outcomes.
• Exploration of combination therapies with other antihypertensives.
• Regulatory pursuit of indications like pulmonary arterial hypertension.

Key Takeaways

• Clinical Trials: Ongoing research suggests expanded indications, notably in pulmonary hypertension and hypertensive pregnancy, though none have yet resulted in new label approvals.
• Market Dynamics: The global Procardia market remains mature with steady growth, underpinned by cardiovascular disease prevalence and patent expirations enabling generic competition.
• Innovation Focus: Formulation enhancements and new indications represent key growth avenues; however, regulatory timelines and market saturation limit rapid expansion.
• Geographical Trends: Emerging markets, especially Asia-Pacific and Latin America, exhibit the highest growth potential owing to increasing healthcare access and cardiovascular disease burden.
• Competitive Strategies: Differentiation through formulation innovation, combination therapies, and clinical evidence are vital for pharmaceutical manufacturers seeking market share expansion.

FAQs

1. What are the main indications currently approved for Procardia?
Procardia (nifedipine) is approved for angina pectoris, hypertension, and preterm labor management.

2. Are there any promising clinical trials investigating new uses of Procardia?
Yes. Trials focusing on pulmonary hypertension and hypertensive pregnancy disorders are underway, though none have yet resulted in regulatory approvals.

3. How saturated is the global market for generic nifedipine?
The market is highly saturated with multiple generics, resulting in price competition but steady demand driven by hypertension prevalence.

4. What are the primary drivers for growth in the Procardia market?
Growth is primarily driven by aging populations, rising cardiovascular disease incidence, and regulatory approvals for expanded indications.

5. How might formulation innovations impact the market outlook?
Extended-release and combination formulations can improve patient adherence and outcomes, opening new revenue streams and market segments.

References

1. EvaluatePharma. "Procardia (Nifedipine) Market Forecasts," 2022.
2. ClinicalTrials.gov. "Nifedipine" Trials Database, 2023.
3. IMS Health. "Global Cardiovascular Drugs Market Report," 2022.
4. US FDA. "Drug Approvals and Labeling," 2022.
5. World Health Organization. "Global Status Report on Noncommunicable Diseases," 2021.